Nadine Kutsch, Adam Giza, Sandra Robrecht, Janina Stumpf, Anno Federhen, Andrea Stoltefuß, Ursula Vehling-Kaiser, Michael Koenigsmann, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Thomas Illmer, Rudolf Schlag, Steffen Dörfel, Tobias Gaska, Michael Kiehl, Sigrun Müller-Hagen, Enno Moorahrend, Hartmut Linde, Anke Schlenska-Lange, Julia von Tresckow, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Anna Maria Fink
Long-term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long-term data collected within the GCLLSG registry. Altogether, 417 CLL patients who received first-line treatment with FCR were analyzed, of which 293 (70.3%) were treated outside of clinical trials. The median observation time from first-line was 95.8 (interquartile range 58.7-126.8) months. Focusing on data of 194 (46...
May 1, 2024: European Journal of Haematology